The balance of chaperones and unfolded proteins in the ER is important to the functionality and health of all secretory cells and affects the outcome of diverse protein-misfolding and aging-related diseases 1,2 . Conserved transcriptional and translational mechanisms, operative on a timescale of hours, match ER folding capacity to client-protein abundance in all eukaryotes 3 . In metazoans this unfolded protein response (UPR) is complemented by processes that rapidly inactivate and reactivate the ER-localized Hsp70 chaperone BiP to match fluctuating levels of unfolded proteins during the inherent delay of the UPR.
a r t i c l e s
The balance of chaperones and unfolded proteins in the ER is important to the functionality and health of all secretory cells and affects the outcome of diverse protein-misfolding and aging-related diseases 1, 2 . Conserved transcriptional and translational mechanisms, operative on a timescale of hours, match ER folding capacity to client-protein abundance in all eukaryotes 3 . In metazoans this unfolded protein response (UPR) is complemented by processes that rapidly inactivate and reactivate the ER-localized Hsp70 chaperone BiP to match fluctuating levels of unfolded proteins during the inherent delay of the UPR.
Two processes are known to contribute to this short-term posttranscriptional buffering. First, client protein binding is in competition with rapid self-binding of BiP to form oligomers that serve as a pool of recruitable inactive chaperone [4] [5] [6] . Second, an enzymatically mediated, inactivating covalent modification of BiP, which is conspicuous when unfolded proteins are scarce 7, 8 , functions alongside mass-action mediated oligomerization to match BiP activity to client protein load. Long believed to be ADP-ribosylation 4, 9 , this modification is now known to be AMPylation [10] [11] [12] ; the covalent attachment of AMP via a phosphodiester bond to the hydroxyl side chain of a residue in the target protein (also known as adenylylation) 13 .
The ER-localized FICD (also known as HYPE) 14 , uses ATP to AMPylate BiP both in vitro and in vivo [10] [11] [12] 15 . In cultured mammalian cells, deletion of the gene FICD abolishes all evidence of BiP modification, which is otherwise observed at high stoichiometry on T518. AMPylated BiP (BiP T518-AMP ) is only weakly stimulated by J domain proteins, and the modified chaperone is locked in a relatively inert state 12 . Similarly to other FIC enzymes, FICD's AMPylation activity is intrinsically repressed by the intramolecular engagement of the regulatory residue E234 in FICD's active site 16, 17 . However, enforced expression of a constitutively AMPylating FICD mutant (which bypasses the aforementioned intrinsic repressive mechanism) results in high levels of ER stress-probably as a consequence of BiP inactivation. These genetic and biochemical findings point to FICD as both necessary and sufficient for BiP AMPylation when the burden of unfolded ER proteins is low.
As unfolded proteins accumulate, pre-existing AMPylated BiP is rapidly converted to the active de-AMPylated state 6, 11, 12 , indicating that BiP AMPylation is a reversible modification that contributes to the balance between clients and chaperone in the ER. Regulatory, de-AMPylating enzymes are known to exist: AMPylated Escherichia coli glutamine synthetase is reactivated by a de-AMPylase encoded by the N-terminal portion of a polypeptide that also encodes the AMPylase 18, 19 , whereas in the course of Legionella pneumophilia infection, the AMPylated, inactivated mammalian host GTPase Rab1 is reactivated by a bacterially encoded de-AMPylating enzyme, SidD 20 . However, the counterparts to such enzymes in the mammalian ER are not obvious. This study therefore addresses the process by which the phosphodiester bond between AMP and the hydroxyl side chain of BiP T518 is broken and full BiP chaperone activity restored.
RESULTS

Effect of FICD overexpression in FICD −/− cells
AMPylated BiP, detected by its characteristic mobility on native PAGE or in isoelectric focusing gels, was readily observed upon inhibition of protein synthesis in wild-type but not FICD −/− cells ( Fig. 1) . However, overexpression of FICD did not restore AMPylation in FICD −/− cells. ER stress caused by FICD overexpression is unlikely to contribute to the lack of AMPylated BiP, as UPR signaling was not activated in the transfected cells (described below). By contrast, a r t i c l e s overexpression of the hyperactive allele FICD E234G readily restored AMPylated BiP in FICD −/− cells 12 (Fig. 1, lanes 4 and 5) .
Unlike recombinantly expressed wild-type FICD, neither endogenous FICD nor the hyperactive FICD E234G were reliably detectable in our immunoblots. This finding reflects the low abundance of endogenous FICD in cells 12 and indicates that, even when greatly overexpressed, the wild-type enzyme is unable to promote AMPylated BiP in FICD −/− cells. This result also suggests the possibility that levels of AMPylated BiP are biphasically related to the concentration of wild-type FICD (but not mutant FICD E234G ) and that in addition to AMPylating BiP wild-type FICD also has a role in undoing the modification-a function that dominates in overexpression-prone trans-rescue experiments.
Effect of FICD on BiP AMPylation in vitro
Speculation that failure to rescue AMPylation reflects a narrow tolerance for FICD dosage effects, consequent to opposing actions of a single FICD enzyme, is further supported by observations that AMPylation and de-AMPylation of bacterial glutamine synthetase is carried out by two structurally-related nucleotidylyl transferase-like domains on the same polypeptide 19 . Although the active sites of glutamine synthetase adenylyl transferase (GS-ATase) are not obviously related to FIC, the FIC fold also flexibly catalyzes diverse phospho-transfer reactions [21] [22] [23] . Therefore, it seemed reasonable to examine the ability of FICD to remove the AMP moiety from BiP T518-AMP .
The signal arising from the 32 P-labeled AMP of purified BiP T518-AMP was very stable, with negligible rates of spontaneous hydrolysis. However, addition of wild-type FICD led to a time-dependent decrease in radiolabel; a feature shared by neither the AMPylation-competent, hyperactive FICD E234G nor the AMPylation-defective FICD H363A mutant enzyme (Fig. 2a) . These de-AMPylation reactions were performed in the absence of ATP, precluding re-AMPylation by any residual hyperactive AMPylating FICD E234G (carried over from the preceding AMPylation reaction). The de-AMPylating activity of wildtype FICD was not restricted to recombinant BiP AMPylated in vitro, as incubating lysates from cycloheximide-treated cells with pure wildtype FICD also led to disappearance of the acidic AMPylated form of endogenous BiP, as revealed by isoelectric focusing (Fig. 2b) .
Wild-type FICD's ability to catalyze the removal of AMP from BiP T518-AMP was confirmed by kinetically following the decline in the fluorescence polarization signal arising from BiP AMPylated in vitro with fluorescent ATP-FAM as a substrate (BiP T518-AMP-FAM ) (Supplementary Fig. 1) . Notably, various substitutions of FICD E234 generated mutant enzymes with widely different constitutive AMPylating activities (Fig. 2c) ; however, all lacked detectable deAMPylating activity (Fig. 2d) , attesting to the dual role of this residue in regulating AMPylation 16, 17 and in affecting de-AMPylation.
Products of FICD-mediated de-AMPylation
To further characterize the FICD-mediated de-AMPylation reaction, we analyzed its products. Comparison of the native mass of unmodified and modified BiP, whether from FICD-containing cells or from samples reacted with FICD and ATP in vitro, points to the addition of a single AMP moiety on any given molecule of BiP 12 . LC-MS analysis of peptides arising from a digest with Arg-C proteinase revealed the presence of a single mono-AMPylated BiP 511-532 peptide (m/z = 1,375.15 (2+)) that was absent from samples of BiP that had never been AMPylated 12 (Fig. 3a, top) . Crucially, this signal was abolished by exposure to wild-type FICD but not to the FICD H363A mutant (Fig. 3a , middle and bottom). The loss of the AMPylated BiP 511-532 peptide caused by FICD was matched by gain in peptides with the mass of the unmodified BiP 511-532 (m/z = 1,209.62 (2+)) (Fig. 3b) , pointing to the ability of FICD to revert BiP T518-AMP to its premodified state.
To examine the fate of the modifying nucleotide, protein-free supernatants of in vitro de-AMPylation reactions were analyzed by ion pair chromatography. Exposure of BiP T518-AMP to wild-type FICD led to the emergence of an absorbance peak at 254 nm that overlapped with the AMP marker (Fig. 3c, red) and had indistinguishable absorption spectra by 3D analysis (Supplementary Fig. 2 ). The AMP peak was conspicuously absent from reactions set up with wild-type FICD and non-AMPylated BiP (Fig. 3c, green) or AMPylated BiP and the inactive FICD H363A mutant (Fig. 3c, blue) . These experiments point to a role of FICD as a phosphodiesterase that liberates AMP from AMPylated BiP.
AMPylated BiP is locked into a low-substrate-affinity, interdomain-coupled state that is relatively resistant to cleavage by SubA 12 , a highly specific protease that cuts the interdomain linker of BiP 24 . Native PAGE revealed that exposure to wild-type FICD imparted sensitivity to SubA on AMPylated BiP (Fig. 3d) . In the absence of ATP, BiP forms higher-order oligomers, a process that is impeded by BiP modification 6 . Exposure to wild-type FICD led to oligomerization of the largely monomeric AMPylated form of BiP (Fig. 3e, lanes 3 and 4) . The FICD-mediated conversion of modified BiP to self-binding unmodified BiP was also noticeable in native gels of samples in presence of ATP, but only BiP dimers were detectable (Fig. 3d, lanes 1 and 2) . Thus, FICD restored BiP to its pre-AMPylated functional state. a r t i c l e s Enzymatic properties of the FICD de-AMPylase FICD-mediated BiP AMPylation is specific for the intact full-length BiP, as the enzyme fails to recognize T518 when the latter is presented in the context of the isolated substrate-binding domain of BiP 12 .
To examine the substrate specificity of FICD's phosphodiesterase activity, the ability of SubA to cleave AMPylated BiP quantitatively (by prolonged incubation) was exploited. Exposure to FICD led to the time-dependent disappearance of the fluorescent signal from intact BiP T518-AMP-FAM . However, FICD was unable to remove the fluorescent moiety from the isolated substrate-binding domain of BiP T518-AMP-FAM (Fig. 4a) . Kinetic analysis of FICD's phosphodiesterase activity revealed the expected enzyme concentration dependence of the reaction (Fig. 4b) , a substrate K M of 15.58 ± 3.27 µM and a k cat of 9.89 ± 0.87 × 10 −3 s −1 (Fig. 4c) . These observations are consistent with a specific but relatively slow de-AMPylase, sensitive to the lower end of physiological fluctuations predicted in the concentration of its substrate. Given that BiP de-AMPylation proceeds in the absence of co-factors or activators, these in vitro observations are consistent with the idea that overexpression of wild-type FICD exposes the ER to high levels of a protein whose default activity is de-AMPylation of BiP.
Role of E234 in FICD-mediated AMPylation cycle
The FICD-mediated BiP AMPylation-de-AMPylation cycle converts the cosubstrate ATP to AMP and pyrophosphate. Therefore, we used the production of AMP in reactions assembled with BiP, ATP and combinations of FICD enzymes to evaluate the relative contributions of AMPylation and de-AMPylation to the apparent inability of wild-type FICD to promote a pool of AMPylated BiP (Figs. 1 and 2c) . No AMP was observed in reactions with the de-AMPylation-defective FICD E234G , consistent with stability of BiP T518-AMP (Fig. 5a , blue trace), however, substantial amounts of AMP were produced over time when wild-type FICD was included alongside the hyperactive mutant FICD E234G (Fig. 5a , red trace, and Fig. 5b) . Notably, AMP was not produced in reactions with wild-type FICD alone (Fig. 5a , black trace). These observations suggest that in the absence of other yetto-be-identified cellular components the wild-type enzyme is locked in an AMPylation-incompetent state, as suggested previously 16, 17 , although it cannot be excluded that the in vitro assay conditions used here selectively interfere with the AMPylation activity of the wildtype enzyme. However, the wild-type enzyme freely de-AMPylates BiP and a single FICD E234G mutation flips the activity of FICD from a constitutive de-AMPylase to a pure AMPylase.
Cellular effects of FICD overexpression
To explore the role of FICD as a BiP de-AMPylating enzyme in vivo, the effect of overexpression of the wild-type enzyme on the level of AMPylated BiP was analyzed in wild-type CHO-K1 cells. Exposure to cycloheximide rapidly led to the emergence of a strong signal of AMPylated BiP, detected by its characteristic mobility on native PAGE gels 12 . This signal was progressively attenuated by overexpression of wild-type FICD (Fig. 6a) , consistent with de-AMPylation of endogenous BiP by overexpressed FICD.
BiP potently represses UPR signaling 25, 26 , whereas inactivation of BiP, by enforced AMPylation, induces the UPR 12 . A role for endogenous FICD in BiP de-AMPylation predicts more UPR activity in FICD −/− cells targeted with de-AMPylation-defective, AMPylation-competent FICD derivatives than in similarly targeted wild-type cells. To test this prediction, the intensity of the UPR was compared between isogenic wild-type and FICD: a r t i c l e s FICD E234G-H363A at similar levels to that of wild-type FICD had no effect on UPR signaling, suggesting an insignificant increase in the unfolded protein load by expression of either FICD. Moreover, de-AMPylationdefective, AMPylation-competent FICD derivatives with mutations at E234 reproducibly induced more UPR signaling in the FICD −/− cells ( Fig. 6b and Supplementary Fig. 3 ). Conversely, coexpression of the wild-type (de-AMPylation-competent) FICD attenuated both accumulation of AMPylated endogenous BiP and UPR signaling induced by the hyperactive FICD E234G (Fig. 6c and Supplementary Fig. 4) . Treatment with the ER stress-inducing compounds tunicamycin or thapsigargin or transfection of effector plasmids expressing the Cas9 nuclease and single guide RNAs that target the BiP-encoding gene promoted similar levels of UPR signaling in wild-type and FICD −/− cells ( Supplementary  Fig. 5 ), attesting to the selective sensitization by the FICD −/− genotype toward effectors that inactivate BiP by AMPylation. BiP inactivation has a large fitness cost 12, 24 . In keeping with a role for endogenous FICD in reversing BiP inactivation by AMPylation, wild-type CHO-K1 cells tolerated stable expression of a retrovirus encoding the de-AMPylation-defective, AMPylation-competent FICD E234G better than FICD −/− cells (Fig. 6d) . Together, these observations point to a role for endogenous FICD in reversing BiP AMPylation and restoring chaperone activity in cells. FICD's E234 lies at the tip of a regulatory helix conserved in other FIC enzymes [21] [22] [23] (Fig. 7) . Engagement of the E234 side chain in the active site, sterically and electronically, delocalizes the terminal phosphates of the bound ATP to repress AMPylation 16, 17 , explaining why wild-type FICD is inactive as an AMPylase in the absence of other factors. However, the E234 side chain is flexible and can, while engaged in the active site, either form a salt bridge with FICD's R374 or retain its charged group to engage in alternative reactions (PDB 4UO4 and 4UOU) such as BiP de-AMPylation.
In vitro, wild-type FICD and the E234G mutant represent the extremes of opposing enzymatic activities. It is likely that other components in the ER specify which of the two activities will prevail at any time, thus sparing the cell fruitless, ATP-consuming cycles of BiP AMPylation and de-AMPylation. It is tempting to speculate that a mechanism exists for coupling the disposition of the E234-containing helix to the burden of unfolded protein in the ER such that when this burden is high the E234 side chain is engaged in the active site a r t i c l e s to block AMPylation and favor de-AMPylation. This appears to be the default conformation of pure FICD, explaining its inability to AMPylate BiP and its constitutive BiP de-AMPylating activity in vitro. When the burden of unfolded proteins is low, a conformational switch in FICD disengages the E234 side chain to promote AMPylation. This proposed short-term mechanism for regulating FICD's intrinsic enzymatic activity functions alongside circuits known to regulate the level of the enzyme, notably the UPR [10] [11] [12] .
The mechanism behind this in vivo switch remains to be worked out; nonetheless, the dominance of de-AMPylation over AMPylation when the wild-type enzyme is overexpressed suggests that in the ER too the default state of E234 is to engage the active site and that an active mechanism, triggered in vivo when the burden of unfolded proteins is low, pries E234 from the active site to convert wild-type FICD to an AMPylase. The machinery for switching FICD from de-AMPylation to AMPylation is absent from the in vitro assays conducted here, but the consequences of its action are mimicked by the E234G substitution, which locks FICD in a constitutively AMPylating mode (Fig. 7) .
The FIC domain is highly flexible in terms of substrate utilization. The bacterial FIC protein DOC has been observed to both phosphorylate and dephosphorylate T382 of bacterial EF-Tu. Analysis of the reaction products indicates that DOC-mediated dephosphorylation is achieved by thermodynamically unfavored reversal of the phosphorylation reaction, regenerating a nucleotide triphosphate 27 . By contrast, the reaction products of FICD-mediated BiP de-AMPylation (unmodified BiP and free AMP) argue against simple mass action-driven enzymatic microreversibility and suggest instead that the active site of FICD catalyzes two interdependent, physiologically antagonistic, chemically distinct reactions.
AMPylation by FIC-domain enzymes employs a conserved HPFX(D/E)GN(G/K)R catalytic loop to position the attacking nucleophile in close proximity to the α-phosphate of the bound ATP substrate [28] [29] [30] . A cocrystal structure of the bacterial enzyme, IbpA, and its AMPylated target, Cdc42, indicates that the same pocket in the FIC active site can accommodate adenosine-phosphate when it is part of the ATP substrate and as part of the AMPylated Cdc42 product 28 . Both AMPylation and de-AMPylation by FICD require the conserved H363. Thus, a shared active site residue contributes to two antagonistic reactions initiated by different attacking nucleophiles.
In AMPylation, FICD mediates a concerted deprotonation and attack of the T518 hydroxyl of BiP on the α-phosphate of the bound ATP substrate 17, 28 . In de-AMPylation the hydroxyl of a water molecule, likely activated by E234, may attack the phosphodiester bond of the bound AMP. It is tempting to speculate that the essential role of FICD's H363 in both reactions reflects deprotonation of the attacking nucleophile in the AMPylation reaction and protonation of the BiP T518 leaving group in the de-AMPylation reaction. 
a r t i c l e s
Our analysis has been restricted to a single FIC enzyme, FICD, and to a single substrate, BiP. The role, if any, of FIC enzymes, and FICD in particular, in demodifying other substrates, remains to be explored. Nor is it known whether all the functional consequences of FICD inactivation can be understood in the context of the enzymes' role in regulating BiP activity. However, in this context the findings presented here are consistent with a model whereby BiP AMPylation evolved as an additional cellular buffer to fluctuations in unfolded ER proteins by acquisition of a single dual-functioning enzyme whose activity is switched in vivo by positioning a conserved regulatory residue. Because BiP AMPylation responds directly to changes in unfolded protein load, without need for gene expression or protein synthesis 11 , the machinery for executing this switch may reveal something about the most proximal steps in protein folding homeostasis in the ER.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
ONLINE METHODS
Cell lines. CHO-K1 cells (ATCC CCL-61) were phenotypically validated as proline auxotrophs, and their Cricitulus griseus origin was confirmed by genomic sequencing. The cells were cultured in Nutrient mixture F-12 Ham (Sigma-Aldrich) supplemented with 10% (v/v) serum (FetalClone II; HyClone), 1× penicillin-streptomycin (Sigma-Aldrich) and 2 mM l-glutamine (Sigma-Aldrich). The CHO-K1 FICD −/− cell lines used in this study were described previously 12 .
HEK293T cells (ATCC CRL-3216) were cultured in DMEM (Sigma-Aldrich) supplemented as described above.
All cells were grown on tissue culture dishes or multi-well plates (Corning) at 37 °C and 5% CO 2 . Cell lines were subjected to random testing for mycoplasma contamination using the MycoAlert Mycoplasma Detection Kit (Lonza). Experiments were performed at cell densities of 60-90% confluence.
Cells were treated with drugs at the following final concentrations: 100 µg/ml cycloheximide (Sigma-Aldrich), 2.5 µg/ml tunicamycin (Melford), 0.5 µM thapsigargin (Calbiochem), and 6-8 µg/ml puromycin (Calbiochem). All drugs were first diluted in fresh, pre-warmed medium and then applied to the cells by medium exchange.
Detailed information on flow cytometry analysis procedures, and production of VSV-G retroviral virus in HEK293T cells and infection of CHO-K1 cells can be found in the Supplementary Note.
Mammalian cell lysates.
Cell lysis was performed as described 6 with modifications. In brief, mammalian cells were cultured on 10-cm dishes and treated as indicated and/or transfected using Lipofectamine LTX with 5 µg plasmid DNA, unless otherwise indicated, and allowed to grow for 24 h. Before lysis the dishes were placed on ice and washed with ice-cold PBS and cells were detached in PBS containing 1 mM EDTA using a cell scraper. The cells were sedimented for 5 min at 370 × g at 4 °C and lysed in HG lysis buffer (20 mM HEPES-KOH, pH 7.4, 150 mM NaCl, 2 mM MgCl 2 , 10 mM d-glucose, 10% (v/v) glycerol, 1% (v/v) Triton X-100) containing protease inhibitors (2 mM PMSF, 4 µg/ml pepstatin A, 4 µg/ml leupeptin, 8 µg/ml aprotinin) with 100 U/ml hexokinase (from Saccharomyces cerevisiae Type F-300; Sigma-Aldrich) for 10 min on ice. The lysates were cleared for 10 min at 21,000 × g at 4 °C. Bio-Rad protein assay reagent (Bio-Rad) was used to determine the protein concentrations of lysates followed by normalization. For analysis by SDS-PAGE, SDS sample buffer was added to the lysates and proteins were denatured by heating for 10 min at 70 °C before separation on 12.5% SDS polyacrylamide gels. To detect endogenous BiP by native PAGE the lysate samples were loaded immediately on native gels (described below). Table 1 lists the plasmids used in this study. Standard PCR and molecular cloning methods were used to generate DNA constructs and point mutations were introduced by PCR-based site-directed mutagenesis.
Plasmid construction. Supplementary
Protein purification. N-terminally hexahistidine-(His 6 )-tagged wild-type and mutant Chinese hamster (Cricetulus griseus) BiP proteins were expressed in M15 E. coli cells (Qiagen). The bacterial cultures were grown at 37 °C to an optical density (OD 600 ) of 0.8 in LB medium supplemented with 50 µg/ml kanamycin and 100 µg/ml ampicillin, and expression of recombinant protein was induced by the addition of 1 mM isopropylthio β-d-1-galactopyranoside (IPTG). The cells were further incubated at 37 °C for 6 h, harvested by centrifugation, and lysed with a high-pressure homogenizer (EmulsiFlex-C3, Avestin) in buffer A (50 mM Tris-HCl, pH 7.5, 500 mM NaCl, 1 mM MgCl 2 , 0.2% (v/v) Triton X-100, 10% (v/v) glycerol, 20 mM imidazole) containing protease inhibitors (2 mM PMSF, 4 µg/ml pepstatin A, 4 µg/ml leupeptin, 8 µg/ml aprotinin) and 0.1 mg/ml DNaseI. The obtained lysates were cleared by centrifugation for 30 min at 45,000 × g and incubated with 1 ml Ni-NTA agarose (Qiagen) per liter of expression culture for 2 h at 4 °C. The matrix was transferred to a column and washed five times with 20 bed volumes of buffer A containing 5 mM β-mercaptoethanol and supplemented sequentially with (i) 30 mM imidazole, (ii) 1% (v/v) Triton X-100, (iii) 1 M NaCl, (iv) 5 mM Mg 2+ -ATP, or (v) 0.5 M Tris-HCl, pH 7.5. Bound BiP proteins were eluted in buffer B (50 mM HEPES-KOH, pH 7.5, 300 mM NaCl, 10% (v/v) glycerol, 5 mM β-mercaptoethanol, 250 mM imidazole) and dialyzed against HKM buffer (50 mM HEPES-KOH, pH 7.4, 150 mM KCl, 10 mM MgCl 2 ). The proteins were concentrated using centrifugal filters (Amicon Ultra, 30 kDa MWCO; Merck Millipore), snap frozen in liquid nitrogen and stored at −80 °C.
Bacterial expression and purification of N-terminally GST-tagged wild-type and mutant FICD proteins was performed as described 12 , with modifications. The FICD-encoding DNA constructs were transformed into C3013 BL21 T7 Express lysY/I q E. coli cells (New England BioLabs), and cultures of single clones were grown at 37 °C in LB medium containing 100 µg/ml ampicillin. At an OD 600 of 0.8 the cultures were shifted to 20 °C, and expression was induced with 0.5 mM IPTG. After incubation for 16 h, the cells were harvested and lysed as described above in lysis buffer (50 mM Tris-HCl, pH 7.5, 500 mM NaCl, 1 mM MgCl 2 , 2 mM dithiothreitol (DTT), 0.2% (v/v) Triton X-100, 10% (v/v) glycerol) containing protease inhibitors and DNaseI. The lysates were cleared by centrifugation for 30 min at 45,000 × g and incubated with 0.7 ml glutathione Sepharose 4B (GE Healthcare) per liter of expression culture for 2 h at 4 °C. The beads were washed with 20 bed volumes wash buffer C (50 mM Tris-HCl, pH 7.5, 500 mM NaCl (Fig. 4a,c) , the protein was eluted from glutathione Sepharose in elution buffer without Triton X-100 and with 1.5 mM DTT. TEV protease was added at a 100:1 (protein to TEV) molar ratio, and after incubation for 16 h at 4 °C the proteins were passed over a size-exclusion chromatography column (Superdex 200 10/300 GL; GE Healthcare) in HKMG buffer (50 mM HEPES-KOH, pH 7.4, 150 mM KCl, 10 mM MgCl 2 , 10% glycerol). The FICDprotein-containing fractions were pooled, concentrated and frozen in aliquots.
Purification of in vitro AMPylated BiP proteins. AMPylated BiP proteins were prepared as described previously 12 , with modifications. In brief, 20 mg purified wild-type BiP or substrate-binding-deficient BiP V461F mutant protein 31 was in vitro AMPylated for 4 h at 30 °C with 0.25 mg bacterially expressed FICD E234G in the presence of 3 mM ATP in buffer E (25 mM HEPES-KOH, pH 7.4, 100 mM KCl, 10 mM MgCl 2 , 1 mM CaCl 2 , 0.1% (v/v) Triton X-100). Afterwards, BiP proteins were bound to 400 µl Ni-NTA agarose affinity matrix for 30 min at 25 °C, washed with buffer E and eluted in buffer E containing 350 mM imidazole for 45 min at 25 °C. The eluate was concentrated and passed over a Centri-Pure P25 desalting column (emp BIOTECH) equilibrated in HKMG buffer. The protein-containing fractions were pooled, concentrated, frozen in liquid nitrogen and stored at −80 °C. BiP was quantitatively AMPylated as judged by the conversion of BiP oligomers into the modified monomeric 'B' form on a native PAGE gel. The modified BiP proteins were used for in vitro de-AMPylation assays and MS analysis (described below). Unmodified BiP prepared from a parallel mock AMPylation reaction without enzyme served as a control.
In vitro AMPylation and de-AMPylation assays. Unless stated otherwise, in vitro AMPylation and de-AMPylation reactions were performed in AMPylation buffer (25 mM HEPES-KOH, pH 7.4, 100 mM KCl, 4 mM MgCl 2 , 1 mM CaCl 2 , 0.1% (v/v) Triton X-100).
Radioactive in vitro AMPylation (Fig. 2c) reactions were set up in a final volume of 37.5 µl containing 1 µM ATP hydrolysis-deficient mutant BiP protein (BiP T229A ) 32 , 0.1 µM wild-type or mutant FICD proteins, 40 µM ATP and 0.023 MBq [α-32 P]ATP (EasyTide; PerkinElmer). The reactions were started by addition of the nucleotides and incubated at 25 °C. After 3 or 10 min of incubation, 15 µl was removed from each reaction, supplemented with 5 µl SDS sample buffer, heated for 5 min at 75 °C and loaded on a SDS-PAGE gel. Gels were stained with Coomassie dye, and the radioactive signals were detected with a Typhoon Trio imager (GE Healthcare) upon overnight exposure of the dried gels to a storage phosphor screen.
For radioactive de-AMPylation experiments (Fig. 2a) , BiP was first AMPylated in vitro with [α-32 P]ATP and then repurified. Therefore, 6 µg purified BiP was pre-incubated with 15 µM ATP in a final volume of 20 µl in AMPylation buffer for 1 min at 25 °C before 1.85 MBq [α-32 P]ATP, and 2 µg FICD E234G was added.
The mixture was incubated for 10 min at 25 °C and another 12 µg BiP was added. After 50 min further incubation, the reaction was diluted with 200 µl high-salt AMPylation buffer (25 mM HEPES-KOH, pH 7.4, 500 mM KCl, 4 mM MgCl 2 , 1 mM CaCl 2 , 0.1% (v/v) Triton X-100), and 1 mM ATP was added. BiP was then bound to 20 µl Ni-NTA agarose beads for 30 min at 20 °C. The beads were washed with 500 µl high-salt AMPylation buffer containing 1 mM ATP and three times with high-salt AMPylation buffer. Bound proteins were eluted in 100 µl AMPylation buffer containing 400 mM imidazole (pH 7.4) for 30 min at 20 °C. The eluate was split in two fractions of 50 µl, and each fraction was passed through a Sephadex G-50 MicroSpin column (illustra AutoSeq G-50; GE Healthcare) equilibrated with AMPylation buffer, and the recovered proteins were frozen in aliquots until the de-AMPylation experiment. The de-AMPylation reactions were carried out at 23 °C in a final volume of 15 µl in AMPylation buffer containing 1.3 µg nonradioactive AMPylated wild-type BiP supplemented with trace amounts of radiolabeled AMPylated BiP (~0.1 µg). The reactions were started at different time points by addition of 0.13 µg wild-type or mutant FICD. At the end of the experiment, 5 µl SDS sample buffer was added to each reaction, proteins were denatured for 5 min at 75 °C, and 15 µl of each sample was applied to SDS-PAGE. After separation, the proteins were stained with Coomassie dye to confirm equal loading, and radioactive signals were detected by autoradiography as described above.
The nonradioactive de-AMPylation reactions shown in Figure 3d contained 1 µg/µl purified AMPylated wild-type BiP and 0.1 µg/µl wild-type or mutant FICD and were incubated for 90 min at 30 °C in a final volume of 25 µl in presence of 3 mM ATP. Afterwards, each reaction was divided into two samples, one of which was treated for 10 min with 0.06 µg/µl SubA protease at 25 °C, the other of which remained untreated. The samples were then supplemented with native sample buffer and analyzed immediately by native PAGE and Coomassie staining (described below). The de-AMPylation reactions shown in Figure 3e were performed in HKM buffer and contained 1 µg/µl purified AMPylated or unmodified wild-type BiP and were incubated without or with 0.05 µg/µl wildtype FICD for 30 min at 30 °C in absence of ATP (to allow reformation of BiP oligomers) before analysis by native PAGE.
The reactions shown in Figure 2b contained 3 µg/µl protein from lysates of untreated wild-type CHO-K1 cells or cells treated for 3 h with CHX, and 0.15 µg/µl purified wild-type or mutant FICD as described above. The reactions were started by addition of purified FICD and incubated at 30 °C. After 15 min, the reactions were diluted 1:10 in IEF lysis buffer and analyzed by IEF (described below). Detailed information on fluorescence polarization assay procedures can be found in Supplementary Note. Mass spectrometry. For MS analysis, purified in vitro AMPylated or unmodified wild-type BiP (Chinese hamster) at 16 µM was incubated with 0.8 µM wild-type FICD or catalytically inactive mutant FICD H363A for 3 h at 30 °C. Afterwards, the proteins were denatured with SDS sample buffer, heated for 5 min at 75 °C and separated by SDS-PAGE. The gels were stained with Coomassie dye and then destained, and bands at 75 kDa, corresponding to BiP protein, were excised. The proteins were then reduced, alkylated, and digested 'in gel' with Arg-C proteinase. The obtained peptides were analyzed by LC-MS using a Q Exactive mass spectrometer (Thermo Fisher) coupled to a RSLC 3000 UHPLC. The data were processed with Proteome Discoverer 1.4 using Sequest to search a Uniprot E. coli database (http://www.uniprot.org/) (downloaded 29 April 2015, 4,377 entries) with the sequence of Chinese hamster BiP added. Oxidation (M), deamidation (N/Q) and AMPylation (S/T) were set as variable modifications, and carbamidomethylation (C) was set as a fixed modification. FDR calculations were performed by Percolator, and peptides were filtered to 1%.
Ion-pair chromatography (IPC).
To detect the leaving group of the FICDmediated de-AMPylation reaction, reversed-phase IPC was performed (Fig. 3c) . Purified in vitro AMPylated or unmodified BiP proteins at 65 µM were exposed to wild-type FICD or FICD H363A proteins at 6.5 µM in HKM buffer in a final volume of 30 µl for 2 h at 30 °C. At the end of the incubation time, the reactions were stopped by addition of 10 µl 4 M perchloric acid (PCA). As a negative control, AMPylated BiP was incubated in parallel for 2 h without enzyme, and FICD was added directly before mixing with PCA. After incubation for 5 min on ice, the samples were centrifuged at 21,000 × g for 2 min at 4 °C, and 32 µl of the supernatants was mixed with 20 µl of 2 M potassium hydroxide (KOH). The pH of the samples was neutralized, the precipitates were sedimented by centrifugation for 15 min at 21,000 × g at 4 °C, and the cleared supernatant was equilibrated to room temperature before analysis by IPC. For that, 20 µl of each sample was injected onto a Poroshell 120 EC-C18 HPLC column (3 × 150 mm, 2.7 µm; Agilent Technologies) connected to a UHPLC Guard column (Agilent Technologies). Buffers A (H 2 O + 10 mM tetrabutylammonium hydroxide (TBAH) + 10 mM potassium dihydrogen phosphate (KH 2 PO 4 )) and B (methanol (CH 3 OH) + 10 mM TBAH) were used as a mobile phase. The runs were performed at a constant flow rate of 0.4 ml/min at room temperature using the following gradient: 5% to 50% B in 25 min, hold for 2 min at 50% B, ramp to 95% B in 0.1 min, hold for 7 min, 95% to 5% B in 1 min, hold for 5 min at 5% B (re-equlibration to basal). Nucleotide absorbance traces at 254 nm (A 254 ) were recorded and plotted against elution time. A nucleotide standard was applied in each experiment to determine the retention times of ATP, ADP and AMP.
Coupled AMPylation-de-AMPylation reactions ( Fig. 3d and Supplementary  Fig. 2 ) contained 20 µM ATP hydrolysis-deficient BiP T229A , 2 µM wild-type FICD, 2 µM FICD E234G and 2 mM ATP in HKM buffer as indicated, and were incubated for 3 h at 30 °C before deproteination and HPLC analysis as described above.
